IMRT Course 2016

Previous Page

Next Page

Page Background

Key trials of neoadjuvant HT plus RT

Trial

Follow-

up

HT

duration

Improved

Not improved

RTOG 86-10

1

10 years

4 months

Disease-specific

mortality, DFS,

biochemical failure

OS, median survival

time

Local progression,

event-free survival

Prostate cancer-

TROG 96.01

2

10 years

3 or 6

months

(3 and 6 months)

All-cause mortality,

prostate cancer

mortality (6 months)

specific mortality,

all-cause mortality

(3 months)

1. Roach M, et al. J Clin Oncol 2008;26:585-91

2. Denham JW, et al. Lancet Oncol 2011;12:451-9

DFS, disease-free survival; HT, hormone therapy

OS, overall survival; RT, radiotherapy

BM1